Homologous recombination deficiency in epithelial ovarian cancer
Open Access
- 21 April 2020
- journal article
- review article
- Published by Springer Nature in memo - Magazine of European Medical Oncology
- Vol. 13 (4) , 367-370
Abstract
Summary: Since the introduction of poly-ADP-ribose polymerase (PARP) inhibitor therapy for epithelial ovarian cancer (EOC) patients, testing for aberrations of homologous recombination (HR) repair as a predictive biomarker of therapy response has become an area of particular clinical interest. As HR represents a crucial repair pathway of otherwise possibly lethal DNA double strand breaks, its deficiency triggers a phenotypic behavior of tumor cells resulting in the accumulation of genetic damage. PARP inhibitors target this emerging genomic instability by fostering DNA strand breaks. Whereas testing for mutations of the tumor-suppressor genes BRCA 1 and BRCA 2 as a pivotal part of the HR apparatus has entered clinical routine, approximately 30% more high-grade EOC patients harbor aberrations of the HR pathway other than BRCA mutations and may therefore respond to PARP inhibition therapy. In recent years, several double-blind, placebo-controlled trials investigating sizeable patient cohorts have reported positive results of PARP inhibitor therapy response in HR-positive patient subgroups. Therefore, introducing HR testing in both the primary and recurrent setting as a biomarker for PARP inhibitor response may expand the range of patients who may profit from this therapeutic option beyond BRCA-mutated tumors.Keywords
Funding Information
- Medical University of Vienna
This publication has 18 references indexed in Scilit:
- Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trialThe Lancet Oncology, 2019
- Controversies in oncology: are genomic tests quantifying homologous recombination repair deficiency (HRD) useful for treatment decision making?ESMO Open, 2019
- PARP inhibitors in platinum-sensitive high-grade serous ovarian cancerCancer Chemotherapy and Pharmacology, 2018
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2017
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trialThe Lancet Oncology, 2017
- Evaluation of BRCA1/2 and homologous recombination defects in ovarian cancer and impact on clinical outcomes.Journal of Clinical Oncology, 2017
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian CancerNew England Journal of Medicine, 2016
- Homologous recombination deficiency and ovarian cancerEuropean Journal of Cancer, 2016
- Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancersBreast Cancer Research, 2014
- Signatures of mutational processes in human cancerNature, 2013